Dozens of biotech companies are running low on cash and face an uphill struggle to raise fresh funds after “tourist” investors who snapped up their shares during the pandemic abandoned the sector.
数十家生物技术公司目前正陷入现金短缺，而且面临着筹集新资金的艰难斗争，原因是那些在大流行期间抢购其股票的“游客”投资者放弃了该行业。
您已阅读2%（263字），剩余98%（10787字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。